LLEO DE NALDA, Ana
 Distribuzione geografica
Continente #
NA - Nord America 4.669
EU - Europa 1.116
AS - Asia 623
AF - Africa 176
SA - Sud America 17
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 6
Totale 6.614
Nazione #
US - Stati Uniti d'America 4.634
SG - Singapore 330
FI - Finlandia 283
CN - Cina 206
IE - Irlanda 205
NG - Nigeria 170
IT - Italia 146
DE - Germania 105
FR - Francia 95
SE - Svezia 76
NL - Olanda 52
GB - Regno Unito 49
CA - Canada 31
BE - Belgio 27
IN - India 23
MK - Macedonia 17
IL - Israele 16
TR - Turchia 16
CZ - Repubblica Ceca 15
RU - Federazione Russa 13
BR - Brasile 9
PH - Filippine 7
IQ - Iraq 6
AT - Austria 5
AU - Australia 5
ES - Italia 5
ET - Etiopia 5
RO - Romania 5
IR - Iran 4
KR - Corea 4
PL - Polonia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AR - Argentina 3
CL - Cile 3
EU - Europa 3
GR - Grecia 3
HK - Hong Kong 3
JP - Giappone 3
MX - Messico 3
NO - Norvegia 3
UA - Ucraina 3
CH - Svizzera 2
NZ - Nuova Zelanda 2
RS - Serbia 2
SA - Arabia Saudita 2
BD - Bangladesh 1
CO - Colombia 1
CU - Cuba 1
MD - Moldavia 1
MN - Mongolia 1
MY - Malesia 1
UG - Uganda 1
VE - Venezuela 1
Totale 6.614
Città #
Chandler 957
Wilmington 825
San Mateo 313
Helsinki 283
Ann Arbor 266
Dublin 205
Singapore 205
Boardman 188
New York 184
Shanghai 180
Benin City 167
Lawrence 155
Princeton 155
Leawood 141
Ashburn 107
Paris 89
Fairfield 70
Woodbridge 70
Milan 54
Amsterdam 47
Seattle 38
London 37
Brussels 27
Phoenix 27
Toronto 27
Los Angeles 18
San Diego 18
Pune 17
Redwood City 17
Abbiategrasso 16
Rome 16
Kocaeli 15
Norwalk 12
Brno 11
Skopje 9
Santa Clara 8
Falkenstein 7
Munich 7
Clearwater 6
Addis Ababa 5
Baghdad 5
Bitola 5
Des Moines 5
Frankfurt am Main 5
Hanover 5
Houston 5
Redmond 5
São Paulo 5
Andover 4
Cologno Monzese 4
Madrid 4
Moscow 4
Olomouc 4
Sacramento 4
Buenos Aires 3
Cambridge 3
Cedar Knolls 3
Cookstown 3
Desio 3
Gunzenhausen 3
Hangzhou 3
Monmouth Junction 3
Novokuznetsk 3
Olongapo City 3
Ottawa 3
Prilep 3
Alexandria 2
Beijing 2
Berlin 2
Buffalo 2
Dallas 2
Esslingen am Neckar 2
Gdansk 2
Hong Kong 2
Kolkata 2
La Canada Flintridge 2
Las Pinas 2
Ness Ziona 2
Newham 2
Parkville 2
Sale Marasino 2
Seocho-gu 2
Torino 2
Venegono Superiore 2
Xingtai 2
Aachen 1
Adelaide 1
At Tuwal 1
Athens 1
Auckland 1
Augusta 1
Birch Run 1
Bogotá 1
Bollebygd 1
Bologna 1
Boston 1
Bussolengo 1
Cagayan de Oro 1
Canberra 1
Casandrino 1
Totale 5.152
Nome #
Outcome of Sars-COV-2-related thyrotoxicosis in survivors of Covid-19: a prospective study 136
Lights and Shadows on Fibrates as Second-Line Therapy of Primary Biliary Cholangitis 76
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 66
X chromosome gene methylation in peripheral lymphocytes from monozygotic twins discordant for scleroderma 65
Apotopes and the biliary specificity of primary biliary cirrhosis 64
The X chromosome and immune associated genes 63
Innate Immunity and Primary Biliary Cirrhosis 61
Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era 61
The consequences of apoptosis in autoimmunity 60
Definition of human autoimmunity - autoantibodies versus autoimmune disease 60
High mortality in COVID-19 patients with mild respiratory disease 60
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 59
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 59
Autophagy: highlighting a novel player in the autoimmunity scenario 58
Interferon α and its contribution to autoimmunity 56
No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals 56
COVID-19 and liver cancer clinical trials: not everything is lost 56
B cell depletion therapy exacerbates murine primary biliary cirrhosis 56
All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis 56
Macrophage morphology correlates with single-cell diversity and prognosis in colorectal liver metastasis 56
Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry 55
The risk of Liver Cancer in Autoimmune Liver Diseases 54
Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis 54
Changes in the Epidemiology of Primary Biliary Cholangitis 54
Is autoimmunity a matter of sex? 54
HLA Class II antigens associated with lupus nephritis in Italian SLE patients 53
Epigenetic investigation of variably X chromosome inactivated genes in monozygotic female twins discordant for primary biliary cirrhosis 53
The Pathogenesis of Primary Biliary Cholangitis: A Comprehensive Review 52
Liver Injury Induced by Immune Checkpoint Inhibitors: An Affordable Risk of Cancer Therapy? 52
Autoimmune hepatitis type 2 associated with an unexpected and transient presence of primary biliary cirrhosis-specific antimitochondrial antibodies: a case study and review of the literature 52
Prevalence and clinical significance of intrahepatic cholangiocellular carcinoma with radiological enhancement pattern mimicking hepatocellular carcinoma 52
BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection? 51
Making sense of Autoantibodies in Cholestatic Liver Diseases 51
Advances in pharmacotherapy for primary biliary cirrhosis 51
Biliary apotopes and antimitochondrial antibodies activate innate immune responses in primary biliary cirrhosis 51
Autoimmunity and Turner's syndrome 51
Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and hepatocellular carcinoma-a composite scenario 50
Evolving trends in female to male incidence and male mortality of primary biliary cholangitis 50
Safety of vedolizumab in liver transplant recipients: A systematic review 50
The limitations and hidden gems of the epidemiology of primary biliary cirrhosis 49
Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosis 49
Lymphoid infiltrate predicts prognosis of mass-forming intrahepatic cholangiocarcinoma undergoing complete liver resection 49
Telomere dysfunction in peripheral blood mononuclear cells from patients with primary biliary cirrhosis 48
Apotopes and innate immune system: Novel players in the primary biliary cirrhosis scenario 48
Benign liver tumors: Diagnostics and treatment 48
Primary biliary cirrhosis and autoimmune hepatitis: apotopes and epitopes 48
Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis 48
Role of liver biopsy in hepatocellular carcinoma 48
Primary biliary cholangitis: a comprehensive overview. 47
Mediterranean diet and NAFLD: What we know and questions that still need to be answered 47
Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis 47
Geoepidemiology, Genetic and Environmental Risk Factors for PBC 47
Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment 47
Interpreting serological tests in diagnosing autoimmune liver diseases 46
Hepatitis C virus eradication with DAA and liver cancer recurrence: is the best the enemy of the good? 46
The X-Factor in Primary Biliary Cirrhosis: Monosomy X and Xenobiotics 46
Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase 46
Genetic associations in Italian primary sclerosing cholangitis : heterogeneity across Europe defines a critical role for HLA-C 46
Mesenchymal Stem Cells to Treat Digestive System Disorders: Progress Made and Future Directions 45
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals 45
Increased loss of the Y chromosome in peripheral blood cells in male patients with autoimmune thyroiditis 45
Levels of Alkaline Phosphatase and Bilirubin are Surrogate Endpoints of Outcomes of Patients with Primary Biliary Cirrhosis - an International Follow-up Study 45
Treatment with PEG-interferon and ribavirin for chronic hepatitis C increases neutrophil and monocyte chemotaxis 44
PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis 44
Hepatotoxicity of immune check point inhibitors: Approach and management 44
The overlap syndrome between primary biliary cirrhosis and primary sclerosing cholangitis 44
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 44
Y chromosome loss in male patients with primary biliary cirrhosis 43
Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases 43
Refining surgical therapy of liver cancer in cirrhosis: etiology makes the difference 43
Is there a real survival benefit of surveillance for hepatocellular carcinoma in cirrhotic patients? 42
Postsustained Virological Response Management in Hepatitis C Patients 42
Comparative analysis of portal cell infiltrates in AMA positive versus AMA negative PBC 42
Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications 42
Genetics and epigenetics of primary biliary cirrhosis 41
Letter to the Editor: might denosumab fit in PBC treatment? 41
The impact of antiviral therapy on hepatocellular carcinoma epidemiology 41
The immunological potential of galectin-1 and 3 41
Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis : a multicenter study of 664 patients and 1992 healthy controls 41
Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery 41
Intrahepatic cholangiocellular carcinoma with radiological enhancement patterns mimicking hepatocellular carcinoma 41
Antimitochondrial Antibodies: from Bench to Bedside 41
Coronary flow reserve is an innovative tool for the early detection of cardiovascular dysfunction in primary biliary cholangitis patients. 40
Etiopathogenesis of primary biliary cirrhosis 40
Common Variable Immunodeficiency and Liver Involvement 40
Primary biliary cirrhosis and autoimmune cholangitis 40
The tumour microenvironment and immune milieu of cholangiocarcinoma 40
Filamin A expression predicts early recurrence of hepatocellular carcinoma after hepatectomy 40
Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells 39
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine 39
Geoepidemiology, gender and autoimmune disease 39
Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma 39
Modulation of CD4(+) T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis 39
Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study 39
Pathway-based analysis of primary biliary cirrhosis genome-wide association studies 39
Towards common denominators in Primary Biliary Cirrhosis: the role of IL-12 38
Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma; its synthesis is reduced favoring cholangiocarcinoma growth 38
Role of cholangiocytes in primary biliary cirrhosis 38
Clinical Outcomes in the Second versus First Pandemic Wave in Italy: Impact of Hospital Changes and Reorganization 38
What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective 37
Totale 4.901
Categoria #
all - tutte 58.230
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.230


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202012 0 0 0 0 0 0 0 0 0 0 0 12
2020/20211.528 24 11 12 12 10 512 214 94 294 177 5 163
2021/2022833 30 10 15 178 8 11 22 109 89 92 201 68
2022/20232.567 349 128 244 319 234 221 13 187 459 205 162 46
2023/20241.616 120 146 347 73 46 220 118 99 34 32 133 248
2024/2025236 55 51 22 60 48 0 0 0 0 0 0 0
Totale 6.792